biotech

Anticancer Drug Against Hodgkin's and Leukemia Granted Orphan Drug Status

Filed in archive Drugs, Vaccines and Therapeutics on January 31, 2006



The European Commission has granted an orphan drug designation to an investigational anticancer drug, 1D09C3, developed for the treatment of Hodgkin's lymphoma and chronic lymphocytic leukemia.

1D09C3 is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. 1D09C3 binds to MHC class II molecules on the surface of cells and selectively kills activated, proliferating tumor cells, which include B-cell and T-cell lymphomas.


1D09C3 is the first internal research program to advance into human trials by GPC Biotech, a Germany-based firm focusing on oncology. Read the full press release from GPC Biotech.

Permalink: Anticancer Drug Against Hodgkin's and Leukemia Granted Orphan Drug Status

Tags: hodgkin  leukemia  drug  biotech  orphan  orphan+drug  granted+orphan  drug+status 

Vote for Anticancer Drug Against Hodgkin's and Leukemia Granted Orphan Drug Status:

  • Currently 8.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 8.00 out of 1 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Tagcloud
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells